Dihexa: A Hepatocyte Growth Factor Mimetic for Synaptogenesis and Cognitive Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to dihexa. Dihexa is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The headline has circulated for over a decade in nootropic communities: a compound ten million times more potent than BDNF at triggering new synaptic connections. That single data point, lifted from an in vitro assay measuring spine formation in cultured neurons, became shorthand for "the most powerful cognitive enhancer ever synthesized." What gets lost is everything the claim does not say: that higher in-vitro molar potency at one narrow biochemical endpoint tells you nothing about clinical efficacy in humans, that no human trial has ever been run, and that the paper originally framing the compound's core biochemistry was retracted in April 2025.

Dihexa is a synthetic angiotensin IV analog developed by Joseph Harding's research group at Washington State University, initially investigated as a potential lead compound for Alzheimer's disease. Here is what the published research actually shows, where the evidence stops, and what the compound's safety unknowns mean in practice.

Key Takeaways

• Regulatory Status: As of April 2026, dihexa is not FDA-approved for any human indication. It has no IND, NDA, or FDA drug classification. It is distributed as a "research use only" chemical through gray-market and online research-chemical vendors.
• Research Stage: Preclinical only. As of April 2026, no completed or ongoing human efficacy trials appear in PubMed or ClinicalTrials.gov. All published cognition data comes from rodent and zebrafish models.
• Availability: Not legally marketed for human use. Superpower Health does not offer dihexa.
• Prescribing information: Dihexa on PubChem (CID 11527385)
• What it is: A small peptidomimetic derived from angiotensin IV, studied as a potential hepatocyte growth factor (HGF) mimetic in rodent cognitive models.
• What the evidence actually shows: Preclinical cognitive restoration in scopolamine-treated and aged rodents; a retracted foundational biochemistry paper; no human data and no published safety profile as of April 2026.

Where Dihexa Comes From and How It Is Proposed to Work

Origin and discovery

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) emerged from a long-running research program at Washington State University led by John Wright and Joseph Harding. The program began in the 1990s investigating the cognitive effects of angiotensin IV (Ang IV), a six-amino-acid fragment of angiotensin II with procognitive properties in rodents. Early Harding-lab work, including a 2001 study by Pederson, Krishnan, Harding, and Wright published in Regulatory Peptides, showed that an early Ang IV analog (Nle1-angiotensin IV) reversed scopolamine-induced spatial memory deficits in rats through hippocampal AT4 receptors. The lab spent the next decade developing metabolically stabilized, orally bioavailable analogs of that scaffold. Dihexa was the optimized lead candidate, described in detail in a 2015 comprehensive review by Wright, Kawas, and Harding published in Progress in Neurobiology, covering the compound's oral bioavailability, blood-brain barrier penetration, and rodent cognitive data.

The AT4/IRAP to HGF/c-Met shift

Understanding dihexa requires tracking a fundamental change in how the Harding lab described its mechanism over time. Angiotensin IV was originally believed to act through the AT4 receptor, later identified as insulin-regulated aminopeptidase (IRAP). A foundational 2001 paper by Albiston, McDowall, and colleagues in the Journal of Biological Chemistry first established IRAP as the AT4 binding site. However, as the group reported in a 2010 study by Albiston, Fernando, and colleagues in Neurobiology of Learning and Memory, IRAP knockout mice showed accelerated age-related spatial memory decline rather than improvement. This paradoxical finding complicated the original mechanism. The Harding lab subsequently moved toward an alternative framing: that dihexa-class molecules produced their cognitive effects by activating the hepatocyte growth factor (HGF) / c-Met receptor system in the brain. This HGF mimetic hypothesis became the dominant framing in the compound's later literature.

The proposed HGF/c-Met synaptogenic mechanism

The procognitive and synaptogenic effects of angiotensin IV-derived peptides including dihexa were proposed by Benoist, Kawas, and colleagues in a 2014 paper in the Journal of Pharmacology and Experimental Therapeutics to depend on activation of the HGF/c-Met receptor system; readers should note that this paper was also formally retracted in April 2025, alongside the 2012 Kawas paper, further eroding the direct biochemical evidence tying dihexa to HGF/c-Met signaling. The mechanistic logic connecting c-Met activation to new synapses draws on independent neuroscience research: Tyndall and Walikonis demonstrated in 2006 in Cell Cycle that c-Met receptors and HGF are physically clustered at excitatory synapses; Tyndall, Patel, and Walikonis extended that work in 2007 in the Journal of Neuroscience Research, showing that HGF enhances dendritic branching in hippocampal neurons through NMDA-receptor-dependent calcium influx and CaMKII activation; Lim and Walikonis showed in 2008 in Cell Signaling that HGF promotes dendritic maturation via the Akt/GSK-3beta pathway; and Xie, Eagleson, and colleagues showed in 2016 in eNeuro that c-Met activation drives beta-catenin-dependent coordination of presynaptic and postsynaptic protein assembly. These findings, none of which involve dihexa directly, provide the mechanistic scaffold for why an HGF mimetic could plausibly promote dendritic spine formation in vitro.

A non-Harding-lab perspective on what the HGF/c-Met pathway does in the brain is provided by a 2021 comprehensive review by Desole, Gallo, Vitacolonna, and colleagues in Frontiers in Cell and Developmental Biology, covering the pathway's pro-angiogenic, anti-inflammatory, and neuroprotective roles in Alzheimer's disease, ALS, and multiple sclerosis. Separately, Kato, Funakoshi, Kadoyama, and colleagues showed in 2012 in the Journal of Neuroscience Research that transgenic HGF overexpression in the mouse nervous system enhances learning and memory, providing independent confirmation that HGF/c-Met activation is procognitive in rodents without relying on Harding-lab data. Shang, Deguchi, Ohta, and colleagues reported in 2011 in the Journal of Neuroscience Research that HGF drives neurogenesis, angiogenesis, synaptogenesis, and antifibrotic effects in rat brain after transient middle cerebral artery occlusion, which supplies additional mechanistic rationale for why an HGF mimetic would be studied in cognitive and neuroregenerative contexts.

The retracted foundational paper

Any article discussing dihexa's HGF mimetic mechanism must acknowledge a critical development in the published record. The paper that originally framed dihexa-class molecules as HGF-dimerization mimetics was published by Kawas, McCoy, Yamamoto, Wright, and Harding in the Journal of Pharmacology and Experimental Therapeutics in 2012 and was formally retracted in April 2025; the retraction notice followed a 2021 Notice of Concern. The follow-up 2014 Benoist, Kawas, and colleagues paper proposing that dihexa-class molecules produce their procognitive effects via HGF/c-Met activation was also formally retracted in April 2025 after a prior 2021 Notice of Concern, and the 2013 McCoy paper that reported oral cognitive restoration with dihexa in scopolamine and aged rats has a 2021 Notice of Concern (not a full retraction). The cumulative effect is that the foundational molecular characterization of dihexa as an HGF-dimerization mimetic and its key behavioral and mechanistic follow-up have been called into question. This is a material fact for any reader evaluating the compound's mechanistic evidence base.

What the Preclinical Research Shows

Rodent cognitive restoration studies

The primary behavioral evidence for dihexa comes from the Harding lab. McCoy, Benoist, Wright, and colleagues published a 2013 study in the Journal of Pharmacology and Experimental Therapeutics evaluating dihexa and related metabolically stabilized Ang IV analogs in Sprague-Dawley rats (intracranial 0.1–1 nmol, intraperitoneal 0.05–0.50 mg/kg, and oral 1.25–2.0 mg/kg doses), with oral dihexa at 2 mg/kg reversing scopolamine-induced deficits in the Morris water maze (group differences p < 0.001) and improving learning in aged 24-month-old rats (p < 0.03). This paper carries a 2021 Notice of Concern from the journal editors regarding possible image manipulation; it has not been formally retracted. This is a genuinely unusual property for a peptidomimetic: oral bioavailability with documented blood-brain barrier penetration in rodents is described as a key distinguishing feature in the Wright, Kawas, and Harding 2015 Progress in Neurobiology review. The parent scaffold producing dihexa was described earlier in a 2011 study by Benoist, Wright, Harding, and colleagues in the Journal of Pharmacology and Experimental Therapeutics, showing that C-terminal truncated Nle1-angiotensin IV analogs facilitated hippocampal synaptogenesis and improved spatial memory.

A 2021 study by Sun and colleagues in Brain Sciences provides external (non-Harding-lab) replication. Sun and colleagues reported that dihexa restored spatial learning on the Morris water maze in APP/PS1 Alzheimer's-model mice and that a PI3K inhibitor reversed the benefit, implicating PI3K/AKT signaling and consistent with the Akt pathway in the c-Met synaptogenesis literature. This is a meaningful data point because it demonstrates that dihexa's preclinical cognitive signal is not confined to the originating laboratory, although this remains a single non-Harding-lab rodent study without independent pharmacokinetic or safety characterization.

The broader angiotensin IV cognition literature

Dihexa exists within a larger literature on Ang IV-class molecules and cognition. A 2018 systematic review by Ho and Nation in Neuroscience and Biobehavioral Reviews synthesized experimental studies on the cognitive benefits of angiotensin IV and angiotensin-(1-7), concluding that evidence of procognitive effects is consistent across multiple rodent models but entirely preclinical. Independent rodent studies have confirmed Ang IV's memory-enhancing properties: De Bundel, Smolders, Yang, and colleagues showed in 2009 in Neurobiology of Learning and Memory that angiotensin IV enhanced spatial working memory in rats through mechanisms unrelated to hippocampal glucose uptake or blood flow; Chow, Tao, Chen, and colleagues reported in 2015 in Neuropeptides that angiotensin IV enhances novel object recognition memory through hippocampal PKMzeta, a memory-consolidation kinase; and Royea, Martinot, and Hamel showed in 2020 in Neurobiology of Disease that Ang IV restored memory and cerebrovascular function in an APP mouse model of Alzheimer's disease. This convergent signal across multiple independent groups supports the biological plausibility of the angiotensin IV cognitive mechanism, though all of it remains animal data.

The "10 million times more potent than BDNF" claim, contextualized

The claim that dihexa is 10 million times more potent than brain-derived neurotrophic factor (BDNF) originates from in vitro synaptogenesis assay results reported in the McCoy 2013 and Benoist 2014 papers. The comparison measures the molar concentration at which each molecule produced half-maximal synaptogenic activity in cultured neurons. At that narrow biochemical endpoint, dihexa showed activity at a far lower concentration than BDNF. That comparison says nothing about comparative clinical efficacy in humans. BDNF has its own complex pharmacology, blood-brain barrier penetration issues, and pleiotropic signaling profile that makes molar potency comparisons in a single in vitro endpoint uninformative as a guide to real-world cognitive effects. The headline is technically grounded in published data and profoundly misleading in how it has been applied.

Negative results

Not every preclinical signal for dihexa has been positive. Wells, Azzam, Hiller, and Sardinia published a 2024 study in the Journal of Huntington's Disease in 40 male Wistar rats showing that PNB-0408 (dihexa) did not protect rats from deficits in body weight, motor function, or spatial learning and memory induced by the mitochondrial toxin 3-nitropropionic acid. The absence of neuroprotective effect in this model is a material data point. It establishes that dihexa's preclinical benefit is not universal across neurodegenerative models, and that the compound cannot be described as a broad-spectrum neuroprotective agent even in animals. A peripheral nerve regeneration study by Weiss and colleagues in 2021 in Annals of Medicine and Surgery similarly found that dihexa alone did not show dramatic benefit in a rat sciatic nerve repair model, though the study explored combination approaches.

Human Evidence: What Exists and What Does Not

The absence of human trials

As of April 2026, a search of PubMed and ClinicalTrials.gov returns no completed or ongoing human clinical trials evaluating dihexa for any indication. No Phase 1 safety study has been published. No pharmacokinetic data in humans has been reported. The entire efficacy evidence base consists of rodent experiments, one zebrafish hair-cell protection study by Uribe, Kawas, Harding, and colleagues published in 2015 in Frontiers in Cellular Neuroscience, and in vitro cell culture experiments. Dihexa was positioned in the Wright and Harding literature as the lead compound for potential Alzheimer's drug development, but that development program has not advanced to human testing. The scientific framing of Alzheimer's disease as a target for HGF/c-Met-based therapeutics was reviewed by Wright and Harding in a 2015 Journal of Alzheimer's Disease article, and the renin-angiotensin system's contributions to memory and cognition were reviewed by Wright and Harding again in a 2019 Journal of Alzheimer's Disease article. The scientific rationale is published. The drug development step, human trials, has not followed.

What rodent data cannot confirm about human effects

Rodent and human brains differ in their HGF/c-Met signaling dynamics, the proportion of hippocampal neuroplasticity to total brain volume, and in species-specific differences in how the angiotensin system modulates cognition. Even within the rodent literature, the Ho and Nation 2018 systematic review observed that most studies used the same behavioral paradigms (radial arm maze, Morris water maze) in the same small-sample experimental designs. The translation from rodent to human for cognitive interventions targeting the HGF pathway has not been established for any compound in this class. The cognitive decline models used (scopolamine-induced amnesia, aged rats, APP/PS1 transgenic mice) are useful screening tools, but they do not accurately model the multifactorial nature of human Alzheimer's disease or age-related cognitive decline.

Regulatory and Legal Status

FDA classification

As of April 2026, dihexa is not FDA-approved for any human indication. It has no Investigational New Drug (IND) application on record, no New Drug Application (NDA), and no FDA drug classification. It is not listed on the FDA's bulk drug substance candidate list under 503A or 503B compounding provisions. There is no legal pathway to obtain pharmaceutical-grade dihexa for human use in the United States. The compound is distributed exclusively through unregulated gray-market channels under "research use only" or "not for human use" labeling.

Gray-market distribution and quality risks

Products labeled as dihexa sold through online research-chemical vendors are not regulated by the FDA for purity, potency, or sterility. This is not a theoretical concern. A 2025 market surveillance study by Vanhee, Deconinck, George, and colleagues published in the Journal of Xenobiotics, involving 12 official European and Australian medicines control laboratories, found that 69% of "smart drug" and nootropic samples came from illegal markets and showed frequent failures in quality, purity, and labeling accuracy. Dihexa circulates in precisely this product category. Consumers who obtain it through gray-market vendors have no means of verifying what they are receiving.

What this means practically

There is no legal prescription pathway for dihexa in the United States. No licensed provider can prescribe it under 503A compounding law because it is not on the approved bulk drug substance list. Anyone encountering dihexa for sale online is looking at an unregulated research chemical with no clinical safety data, no pharmaceutical-grade manufacturing oversight, and active regulatory ambiguity about its legal status as a consumer product. Questions about the regulatory and legal dimensions of compounds like dihexa fall within the scope of specialized regulatory analysis; Superpower routes those questions through Mendel, its regulatory expert resource.

Safety: What Is and Is Not Known

The c-Met oncogenic concern

The most significant theoretical safety concern with dihexa is not a minor caveat. c-Met is a validated cancer drug target precisely because aberrant HGF/c-Met signaling drives tumor proliferation, invasion, angiogenesis, and metastasis across multiple cancer types. An authoritative 2018 review by Comoglio, Trusolino, and Boccaccio in Nature Reviews Cancer documents MET as an oncogene whose activation promotes cancer progression, with the entire clinical oncology trajectory focused on c-Met inhibitors rather than agonists. A 2021 comprehensive review of the HGF/c-MET pathway in cancer by Fu, Su, Li, and colleagues published in Oncogene characterizes the molecular mechanisms by which HGF/c-Met drives tumor growth across tumor types. Dihexa is proposed to act as an agonist at this same receptor system. A systemically bioavailable c-Met agonist that crosses the blood-brain barrier in humans has never been safety-tested for tumor-promoting effects. No chronic toxicology data, genotoxicity data, reproductive toxicity data, or carcinogenicity data has been published for dihexa. This theoretical oncogenic risk is not dismissed by the Harding-lab literature; it is simply uncharacterized.

Context from the same research group reinforces why this concern is substantive rather than hypothetical. Kawas, Yamamoto, Wright, and Harding published a 2011 study in the Journal of Pharmacology and Experimental Therapeutics, cited as Kawas et al. 2011, showing that molecules mimicking the HGF dimerization domain exhibit anti-Met and anticancer activity in cancer cell lines. The same group working to develop an HGF agonist also validated that HGF/c-Met is a legitimate oncology target. Both findings cannot be accommodated simultaneously without confronting the risk that a systemic HGF/c-Met agonist could promote cancer progression in cells with pre-existing or subclinical malignant changes.

Absence of clinical safety data

Beyond the c-Met oncogenic concern, no human safety data of any kind has been published for dihexa. There is no published Phase 1 dose-escalation study. There is no human pharmacokinetic profile. There is no published characterization of adverse effects in humans. The rodent studies that form the entire published efficacy evidence base do not include systematic toxicology reporting at the detail level required for human safety evaluation. This represents a total safety knowledge gap, not a gap that will be resolved by inference from mechanism or from anecdotal user reports on research-chemical forums.

Risks from unregulated sources

Dihexa sold online is an unregulated research chemical. Independent testing of nootropic and peptide products sold through gray-market channels has consistently found contamination, incorrect concentration, and misidentified compounds. The absence of pharmaceutical manufacturing oversight means that potency, purity, and sterility cannot be assumed. Given the compound's unknown human pharmacokinetics and the absence of any established therapeutic dose, concentration errors in unregulated products carry unpredictable consequences.

Who Should Not Use Dihexa

Because no human safety data exists, formal contraindications cannot be established. Based on the compound's proposed mechanisms, the following groups face elevated theoretical risk and should be especially cautious about any exposure:

• Individuals with active cancer or a personal or family history of cancer: dihexa's proposed c-Met agonism activates a pathway that drives tumor proliferation, invasion, and metastasis in multiple cancer types, as documented in oncology literature independent of the Harding-lab cognitive research program
• Individuals with uncharacterized precancerous lesions: the same theoretical oncogenic concern applies even in the absence of a confirmed cancer diagnosis
• Pregnant or breastfeeding individuals: no safety data exists for these populations, and HGF/c-Met signaling is active in fetal development
• Individuals with autoimmune conditions involving aberrant tissue growth or vascular proliferation: HGF/c-Met activation may theoretically exacerbate these processes
• Competitive athletes subject to anti-doping testing: dihexa is a non-approved substance that would be classified under the S0 category of the WADA Prohibited List, which prohibits any pharmacological substance not approved for human therapeutic use by any regulatory authority

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

Understanding your biological baseline is a reasonable starting point regardless of what compounds you are researching. Given dihexa's proposed cognitive mechanism and its theoretical safety concerns, several measurable markers are directly relevant.

• IGF-1: Insulin-like growth factor 1 reflects growth factor signaling activity broadly and is the primary clinical marker tracked in the context of growth factor-related interventions. The IGF-1 blood test provides a baseline for this axis before engaging with any compound that interacts with growth factor receptor systems.
• Cognitive and neurological biomarkers: For individuals concerned about cognitive trajectory, biomarkers relevant to neurotransmitter and cognitive longevity (including homocysteine, vitamin B12, folate, and thyroid markers) establish whether recognized, addressable contributors to cognitive decline are present before exploring research-stage compounds.
• Inflammatory markers (hs-CRP): Neuroinflammation is increasingly recognized as a driver of cognitive decline, and systemic inflammatory markers provide indirect signal. Baseline markers relevant to mental clarity and focus include inflammatory markers that are well-characterized and clinically actionable.
• Liver function panel (ALT, AST, GGT): Because dihexa is studied in the context of HGF, a hepatocyte growth factor (hepatocyte refers to liver cells), liver function markers provide relevant baseline context. Any compound that activates a pathway named for hepatocyte effects warrants liver function monitoring.
• Comprehensive metabolic panel: General organ function (kidney, liver, glucose regulation) establishes safety context for any investigational compound. This is standard baseline monitoring recommended before exploring any research-stage substance.
• PSA (for men): Given the c-Met oncogenic concern and dihexa's proposed systemic bioavailability, a prostate-specific antigen baseline is a reasonable precaution for men before engaging with any systemically active compound that activates a receptor pathway associated with prostate cancer proliferation.

When to Take This Seriously

If you are experiencing cognitive changes, memory difficulties, or age-related mental performance concerns, those are real and well-documented phenomena with established clinical evaluation pathways. A neurologist or primary care physician can assess for reversible causes: thyroid dysfunction, B12 deficiency, sleep-disordered breathing, vascular risk factors, and depression all affect cognitive function and are identifiable through standard testing. The HGF/c-Met pathway is a legitimate area of Alzheimer's disease research, and dihexa is a compound of genuine scientific interest. But "scientifically interesting in animal models" is categorically different from "safe or effective in humans." The gap between those two positions is precisely the space that human clinical trials are designed to bridge, and those trials have not been run for dihexa.

The commitment to data before decisions is what shapes Superpower's approach to preventive health: the belief that understanding your biology through objective measurement is the foundation for every health decision, especially when evaluating compounds at the frontier of research where human evidence does not yet exist.

IMPORTANT SAFETY INFORMATION

Regulatory status: As of April 2026, dihexa is not FDA-approved for any human indication. It has no Investigational New Drug application, New Drug Application, or FDA drug classification. It is not approved for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Superpower Health does not prescribe, sell, compound, or facilitate access to dihexa. Superpower is a technology platform that connects members with licensed healthcare providers and laboratory testing services. Superpower does not prescribe or dispense medications.

No human safety data: No Phase 1 safety study, pharmacokinetic study, chronic toxicology study, or genotoxicity study has been published for dihexa in humans. The compound's human safety profile is entirely uncharacterized.

Theoretical oncogenic concern: Dihexa is proposed to act as an agonist at the HGF/c-Met receptor system. c-Met is a validated oncology drug target because its activation drives tumor proliferation, invasion, and metastasis across multiple cancer types. The tumor-promoting potential of systemic c-Met agonism in humans has never been characterized in clinical studies. This is the most significant unresolved safety concern for this compound.

Retracted foundational papers: The 2012 Kawas et al. paper in the Journal of Pharmacology and Experimental Therapeutics, which originally described dihexa-class molecules as HGF-dimerization mimetics, was formally retracted in April 2025 following a 2021 Notice of Concern. The 2014 Benoist et al. paper in the same journal, proposing that angiotensin IV-derived peptides act via the HGF/c-Met system, was also retracted in April 2025 following a 2021 Notice of Concern. The 2013 McCoy et al. paper reporting oral cognitive restoration in rats carries a 2021 Notice of Concern.

Unregulated source risk: Dihexa is distributed exclusively through gray-market research-chemical vendors. Products sold through these channels are not regulated for purity, potency, or sterility. Independent market surveillance studies have found frequent quality, concentration, and labeling failures in this product category.

Do not use if: you have active cancer or a personal history of cancer; you are pregnant or breastfeeding; you are a competitive athlete subject to anti-doping testing (dihexa would be classified as a prohibited non-approved substance under WADA S0 rules). This is not a complete list of risks. This page is not a substitute for medical advice. Always consult a qualified healthcare provider before making any decisions about investigational compounds.

Additional Questions

Is dihexa safe?

No human safety data exists for dihexa as of April 2026. No Phase 1 dose-escalation study, pharmacokinetic profile, or systematic adverse-event characterization has been published. The compound's proposed c-Met agonist mechanism raises a specific theoretical oncogenic concern, because c-Met activation drives tumor proliferation across multiple cancer types. This is not a minor caveat. It is the single most significant safety unknown for a compound being circulated in consumer nootropic markets with no clinical oversight.

Does dihexa work for cognitive enhancement in humans?

There is no human evidence on which to base an answer to this question. All published cognition data for dihexa comes from rodent models. No human efficacy trial has been completed or is currently registered as ongoing on ClinicalTrials.gov as of April 2026. The preclinical signal is real and has been partially replicated by independent laboratories in rodents. Whether it translates to humans is unknown.

What is the difference between dihexa and other nootropic peptides?

Dihexa is structurally a small peptidomimetic derived from angiotensin IV, with proposed oral bioavailability and blood-brain barrier penetration in rodents, properties that distinguish it from most injectable research peptides. Its proposed mechanism through the HGF/c-Met receptor system is distinct from peptides acting on growth hormone secretagogue receptors, BDNF pathways, or acetylcholine systems. Its most notable distinguishing feature in the current literature is the combination of preclinical cognitive signal, retracted foundational biochemistry paper, zero human data, and a theoretical oncogenic concern that remains uncharacterized.